Pegylated L-Asparaginase
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 14/819,305, filed Aug 5, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,046,946 | Pegylated L-Asparaginase In force · Low confidence UsedRemaining | Jazz Pharmaceuticals II SAS | In force | Low confidence | ||
| US 12,441,992 | Method of treating AML with PEGylated L-Asparaginase In force · Medium confidence | Jazz Pharmaceuticals II SAS | In force | Medium confidence | ||
| US RE49,736 | Pegylated L-Asparaginase In force · Low confidence | Jazz Pharmaceuticals II SAS | In force | Low confidence | ||
| US 9,920,311 | Pegylated L-asparaginase Surrendered on reissue Nov 28, 2023 Low confidence | Jazz Pharmaceuticals II SAS | Surrendered on reissue Nov 28, 2023 | Low confidence | ||
| Application 15/886,216 | Pegylated L-Asparaginase Abandoned Abandoned Jun 7, 2020 | Jazz Pharmaceuticals II SAS | Abandoned | Abandoned Jun 7, 2020 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Jazz Pharmaceuticals II SAS.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.